Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients.

Lucas AT, Robinson R, Schorzman AN, Piscitelli JA, Razo JF, Zamboni WC.

Antibodies (Basel). 2019 Jan 1;8(1). pii: E3. doi: 10.3390/antib8010003. Review.

2.

Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG.

McSweeney MD, Price LSL, Wessler T, Ciociola EC, Herity LB, Piscitelli JA, DeWalle AC, Harris TN, Chan AKP, Saw RS, Hu P, Jennette JC, Forest MG, Cao Y, Montgomery SA, Zamboni WC, Lai SK.

J Control Release. 2019 Oct;311-312:138-146. doi: 10.1016/j.jconrel.2019.08.017. Epub 2019 Aug 24.

PMID:
31454530
3.

Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.

Parker CL, McSweeney MD, Lucas AT, Jacobs TM, Wadsworth D, Zamboni WC, Lai SK.

Nanomedicine. 2019 Oct;21:102076. doi: 10.1016/j.nano.2019.102076. Epub 2019 Aug 5.

PMID:
31394261
4.

Patterns and characteristics associated with surface contamination of hazardous drugs in hospital pharmacies.

Salch SA, Zamboni WC, Zamboni BA, Eckel SF.

Am J Health Syst Pharm. 2019 Apr 17;76(9):591-598. doi: 10.1093/ajhp/zxz033.

PMID:
31361828
5.

Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer.

Taylor SE, Petschauer JS, Donovan H, Schorzman A, Razo J, Zamboni WC, Edwards RP, Zorn KK.

Int J Gynecol Cancer. 2019 Jan;29(1):147-152. doi: 10.1136/ijgc-2018-000055.

PMID:
30640697
6.

Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients.

Starling BR, Kumar P, Lucas AT, Barrow D, Farnan L, Hendrix L, Giovinazzo H, Song G, Gehrig P, Bensen JT, Zamboni WC.

Cancer Chemother Pharmacol. 2019 Jan;83(1):61-70. doi: 10.1007/s00280-018-3702-9. Epub 2018 Oct 16.

7.

Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations.

Zamboni WC, Szebeni J, Kozlov SV, Lucas AT, Piscitelli JA, Dobrovolskaia MA.

Adv Drug Deliv Rev. 2018 Nov - Dec;136-137:82-96. doi: 10.1016/j.addr.2018.09.012. Epub 2018 Sep 29. Review.

PMID:
30273617
8.

Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents.

Schorzman AN, Lucas AT, Kagel JR, Zamboni WC.

Methods Mol Biol. 2018;1831:201-228. doi: 10.1007/978-1-4939-8661-3_15.

PMID:
30051434
9.

A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.

McSweeney MD, Wessler T, Price LSL, Ciociola EC, Herity LB, Piscitelli JA, Zamboni WC, Forest MG, Cao Y, Lai SK.

J Control Release. 2018 Aug 28;284:171-178. doi: 10.1016/j.jconrel.2018.06.002. Epub 2018 Jun 5.

10.

Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer.

Byrne JD, Jajja MRN, O'Neill AT, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ.

Cancer Chemother Pharmacol. 2018 Jun;81(6):991-998. doi: 10.1007/s00280-018-3570-3. Epub 2018 Mar 30.

11.

Factors Affecting the Pharmacology of Antibody-Drug Conjugates.

Lucas AT, Price LSL, Schorzman AN, Storrie M, Piscitelli JA, Razo J, Zamboni WC.

Antibodies (Basel). 2018 Feb 7;7(1). pii: E10. doi: 10.3390/antib7010010. Review.

12.

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC.

Clin Breast Cancer. 2018 Aug;18(4):289-297. doi: 10.1016/j.clbc.2017.10.014. Epub 2017 Oct 28.

13.

Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study.

Risselada M, Linder KE, Griffith E, Roberts BV, Davidson G, Zamboni WC, Messenger KM.

PLoS One. 2017 Oct 5;12(10):e0186018. doi: 10.1371/journal.pone.0186018. eCollection 2017.

14.

Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer.

Madden AJ, Oberhardt B, Lockney D, Santos C, Vennam P, Arney D, Franzen S, Lommel SA, Miller CR, Gehrig P, Zamboni WC.

Nanomedicine (Lond). 2017 Oct;12(20):2519-2532. doi: 10.2217/nnm-2016-0421. Epub 2017 Sep 27.

PMID:
28952882
15.

It takes a village to raise awareness of and to address surface contamination of hazardous drugs.

Zamboni WC, Salch SA, Cox J, Eckel S.

J Oncol Pharm Pract. 2017 Oct;23(7):558-560. doi: 10.1177/1078155217724650. Epub 2017 Aug 9. No abstract available.

PMID:
28791909
16.

Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.

Lucas AT, Price LS, Schorzman A, Zamboni WC.

Nanomedicine (Lond). 2017 Aug;12(16):2021-2042. doi: 10.2217/nnm-2017-0101. Epub 2017 Jul 26. Review.

17.

MerTK as a therapeutic target in glioblastoma.

Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR.

Neuro Oncol. 2018 Jan 10;20(1):92-102. doi: 10.1093/neuonc/nox111.

18.

Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs.

Lucas AT, Herity LB, Kornblum ZA, Madden AJ, Gabizon A, Kabanov AV, Ajamie RT, Bender DM, Kulanthaivel P, Sanchez-Felix MV, Havel HA, Zamboni WC.

Int J Pharm. 2017 Jun 30;526(1-2):443-454. doi: 10.1016/j.ijpharm.2017.04.079. Epub 2017 May 2.

PMID:
28473237
19.

Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.

Bowerman CJ, Byrne JD, Chu KS, Schorzman AN, Keeler AW, Sherwood CA, Perry JL, Luft JC, Darr DB, Deal AM, Napier ME, Zamboni WC, Sharpless NE, Perou CM, DeSimone JM.

Nano Lett. 2017 Jan 11;17(1):242-248. doi: 10.1021/acs.nanolett.6b03971. Epub 2016 Dec 22.

20.

Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models.

Lucas AT, White TF, Deal AM, Herity LB, Song G, Santos CM, Zamboni WC.

Nanomedicine. 2017 Feb;13(2):471-482. doi: 10.1016/j.nano.2016.09.015. Epub 2016 Oct 5.

PMID:
27720926
21.

Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains.

Song G, Suzuki OT, Santos CM, Lucas AT, Wiltshire T, Zamboni WC.

Nanomedicine. 2016 Oct;12(7):2007-2017. doi: 10.1016/j.nano.2016.05.019. Epub 2016 Jun 9.

PMID:
27288666
22.

Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian Cancer.

Patel NR, Piroyan A, Nack AH, Galati CA, McHugh M, Orosz S, Keeler AW, O'Neal S, Zamboni WC, Davis B, Coleman TP.

Mol Pharm. 2016 Jun 6;13(6):1996-2009. doi: 10.1021/acs.molpharmaceut.6b00149. Epub 2016 May 24.

PMID:
27170232
23.

Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.

Byrne JD, Jajja MR, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2200-5. doi: 10.1073/pnas.1600421113. Epub 2016 Feb 8.

24.

Challenges in preclinical to clinical translation for anticancer carrier-mediated agents.

Lucas AT, Madden AJ, Zamboni WC.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Sep;8(5):642-53. doi: 10.1002/wnan.1394. Epub 2016 Feb 5. Review.

PMID:
26846457
25.

Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.

Giovinazzo H, Kumar P, Sheikh A, Brooks KM, Ivanovic M, Walsh M, Caron WP, Kowalsky RJ, Song G, Whitlow A, Clarke-Pearson DL, Brewster WR, Van Le L, Zamboni BA, Bae-Jump V, Gehrig PA, Zamboni WC.

Cancer Chemother Pharmacol. 2016 Mar;77(3):565-73. doi: 10.1007/s00280-015-2945-y. Epub 2016 Jan 28.

PMID:
26822231
26.

A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues.

Lucas AT, O'Neal SK, Santos CM, White TF, Zamboni WC.

J Pharm Biomed Anal. 2016 Feb 5;119:122-9. doi: 10.1016/j.jpba.2015.11.035. Epub 2015 Nov 28.

27.

Development and evaluation of a novel product to remove surface contamination of hazardous drugs.

Cox J, Speed V, O'Neal S, Hasselwander T, Sherwood C, Eckel SF, Zamboni WC.

J Oncol Pharm Pract. 2017 Mar;23(2):103-115. doi: 10.1177/1078155215621151. Epub 2016 Jul 9.

PMID:
26673538
28.

Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance.

Kai MP, Brighton HE, Fromen CA, Shen TW, Luft JC, Luft YE, Keeler AW, Robbins GR, Ting JP, Zamboni WC, Bear JE, DeSimone JM.

ACS Nano. 2016 Jan 26;10(1):861-70. doi: 10.1021/acsnano.5b05999. Epub 2015 Dec 2.

29.

Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT).

Madden AJ, Rawal S, Sandison K, Schell R, Schorzman A, Deal A, Feng L, Ma P, Mumper R, DeSimone J, Zamboni WC.

J Nanopart Res. 2014 Nov 1;16(11). pii: 2662.

30.

Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.

Wallace BD, Roberts AB, Pollet RM, Ingle JD, Biernat KA, Pellock SJ, Venkatesh MK, Guthrie L, O'Neal SK, Robinson SJ, Dollinger M, Figueroa E, McShane SR, Cohen RD, Jin J, Frye SV, Zamboni WC, Pepe-Ranney C, Mani S, Kelly L, Redinbo MR.

Chem Biol. 2015 Sep 17;22(9):1238-49. doi: 10.1016/j.chembiol.2015.08.005. Epub 2015 Sep 10.

31.

Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.

Lucas AT, Madden AJ, Zamboni WC.

Expert Opin Drug Metab Toxicol. 2015;11(9):1419-33. doi: 10.1517/17425255.2015.1057496. Epub 2015 Jul 20. Review.

PMID:
26173794
32.

Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.

Taylor SE, Li R, Petschauer JS, Donovan H, O'Neal S, Keeler AW, Zamboni WC, Edwards RP, Zorn KK.

Gynecol Oncol. 2015 Sep;138(3):548-53. doi: 10.1016/j.ygyno.2015.06.026. Epub 2015 Jun 23.

PMID:
26111788
33.

Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.

Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoshchenko RG, Hanna SK, Ramanathan RK, Lee CR, Bae-Jump VL, Gehrig PA, Zamboni WC.

Nanomedicine. 2015 Oct;11(7):1797-807. doi: 10.1016/j.nano.2015.05.007. Epub 2015 Jun 17.

PMID:
26093057
34.

Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle.

Kai MP, Keeler AW, Perry JL, Reuter KG, Luft JC, O'Neal SK, Zamboni WC, DeSimone JM.

J Control Release. 2015 Apr 28;204:70-7. doi: 10.1016/j.jconrel.2015.03.001. Epub 2015 Mar 3.

35.

Initial locomotor sensitivity to cocaine varies widely among inbred mouse strains.

Wiltshire T, Ervin RB, Duan H, Bogue MA, Zamboni WC, Cook S, Chung W, Zou F, Tarantino LM.

Genes Brain Behav. 2015 Mar;14(3):271-80. doi: 10.1111/gbb.12209.

36.

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd, Zamboni WC.

Int J Nanomedicine. 2015 Feb 10;10:1201-9. doi: 10.2147/IJN.S62911. eCollection 2015. Erratum in: Int J Nanomedicine. 2019 Jul 24;14:5751-5752.

37.

The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.

Petschauer JS, Madden AJ, Kirschbrown WP, Song G, Zamboni WC.

Nanomedicine (Lond). 2015 Feb;10(3):447-63. doi: 10.2217/nnm.14.179. Review.

38.

Local iontophoretic administration of cytotoxic therapies to solid tumors.

Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM.

Sci Transl Med. 2015 Feb 4;7(273):273ra14. doi: 10.1126/scitranslmed.3009951.

39.

Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.

Song G, Darr DB, Santos CM, Ross M, Valdivia A, Jordan JL, Midkiff BR, Cohen S, Nikolaishvili-Feinberg N, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC.

Clin Cancer Res. 2014 Dec 1;20(23):6083-95. doi: 10.1158/1078-0432.CCR-14-0493. Epub 2014 Sep 17.

40.

Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases.

Song G, Petschauer JS, Madden AJ, Zamboni WC.

Curr Rheumatol Rev. 2014;10(1):22-34. Review.

PMID:
25229496
41.

2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.

Peng L, Schorzman AN, Ma P, Madden AJ, Zamboni WC, Benhabbour SR, Mumper RJ.

Int J Nanomedicine. 2014 Jul 30;9:3601-10. doi: 10.2147/IJN.S66040. eCollection 2014.

42.

Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.

Chu KS, Finniss MC, Schorzman AN, Kuijer JL, Luft JC, Bowerman CJ, Napier ME, Haroon ZA, Zamboni WC, DeSimone JM.

Nano Lett. 2014 Mar 12;14(3):1472-6. doi: 10.1021/nl4046558. Epub 2014 Feb 24.

43.

Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation.

Yang Q, Jones SW, Parker CL, Zamboni WC, Bear JE, Lai SK.

Mol Pharm. 2014 Apr 7;11(4):1250-8. doi: 10.1021/mp400703d. Epub 2014 Mar 25.

PMID:
24521246
44.

From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system.

Smith MJ, Brown JM, Zamboni WC, Walker NJ.

Toxicol Sci. 2014 Apr;138(2):249-55. doi: 10.1093/toxsci/kfu005. Epub 2014 Jan 15. Review.

45.

Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.

Caron WP, Lay JC, Fong AM, La-Beck NM, Kumar P, Newman SE, Zhou H, Monaco JH, Clarke-Pearson DL, Brewster WR, Van Le L, Bae-Jump VL, Gehrig PA, Zamboni WC.

J Pharmacol Exp Ther. 2013 Dec;347(3):599-606. doi: 10.1124/jpet.113.208801. Epub 2013 Sep 16.

46.

Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.

Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd, Zamboni WC.

Eur J Clin Pharmacol. 2013 Dec;69(12):2073-81. doi: 10.1007/s00228-013-1580-y. Epub 2013 Aug 30.

PMID:
23989300
47.

Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy.

Chu KS, Schorzman AN, Finniss MC, Bowerman CJ, Peng L, Luft JC, Madden AJ, Wang AZ, Zamboni WC, DeSimone JM.

Biomaterials. 2013 Nov;34(33):8424-9. doi: 10.1016/j.biomaterials.2013.07.038. Epub 2013 Jul 27.

48.

Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.

Schell RF, Sidone BJ, Caron WP, Walsh MD, White TF, Zamboni BA, Ramanathan RK, Zamboni WC.

Nanomedicine. 2014 Jan;10(1):109-17. doi: 10.1016/j.nano.2013.07.005. Epub 2013 Jul 24.

49.

Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.

Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L, Miller CR, Perou CM, Sharpless N, Zamboni WC.

PLoS One. 2013 May 1;8(5):e61359. doi: 10.1371/journal.pone.0061359. Print 2013.

50.

A review of study designs and outcomes of phase I clinical studies of nanoparticle agents compared with small-molecule anticancer agents.

Caron WP, Morgan KP, Zamboni BA, Zamboni WC.

Clin Cancer Res. 2013 Jun 15;19(12):3309-15. doi: 10.1158/1078-0432.CCR-12-3649. Epub 2013 Apr 25.

Supplemental Content

Loading ...
Support Center